KENNETH WALWORTH: Open Payments
NPI 1881096196 · OWOSSO, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$957 in 55 payments from 8 companies in 2025. Trend: 2023 $646 · 2024 $580 · 2025 $957
Food & beverage: $958
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $368 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $238 |
| Alkermes, Inc. | 5 | $121 |
| ABBVIE INC. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Janssen Pharmaceuticals, Inc | 2 | $40 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
Products named: CAPLYTA, REXULTI, ABILIFY MAINTENA, ARISTADA, VRAYLAR, FANAPT, Auvelity, INVEGA SUSTENNA.
Industry payments across MI — which companies pay providers there.
